• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=22773810).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
  

PubMed=21734175; DOI=10.1126/scitranslmed.3002356; PMCID=PMC3500629
Chmielecki J., Foo J., Oxnard G.R., Hutchinson K., Ohashi K., Somwar R., Wang L., Amato K.R., Arcila M.E., Sos M.L., Socci N.D., Viale A.J., de Stanchina E., Ginsberg M.S., Thomas R.K., Kris M.G., Inoue A., Ladanyi M., Miller V.A., Michor F., Pao W.
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Sci. Transl. Med. 3:90ra59.1-90ra59.10(2011)

PubMed=22773810; DOI=10.1073/pnas.1203530109; PMCID=PMC3411967
Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J., Lin Y.-L., Pan Y.-M., Wang L., de Stanchina E., Shien K., Aoe K., Toyooka S., Kiura K., Fernandez-Cuesta L., Fidias P., Yang J.C.-H., Miller V.A., Riely G.J., Kris M.G., Engelman J.A., Vnencak-Jones C.L., Dias-Santagata D., Ladanyi M., Pao W.
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Proc. Natl. Acad. Sci. U.S.A. 109:E2127-E2133(2012)

PubMed=23733853; DOI=10.1101/gr.152322.112; PMCID=PMC3759720
Jia P.-L., Jin H.-L., Meador C.B., Xia J.-F., Ohashi K., Liu L., Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
Genome Res. 23:1434-1445(2013)